Evidence map›Paper›PMID 31020665›Full record

ArticleClinical cardiology2019

Ankle-brachial index, arterial stiffness, and biomarkers in the prediction of mortality and outcomes in patients with end-stage kidney disease.

Kenichiro Otsuka, Koki Nakanishi, Kenei Shimada, Haruo Nakamura, Hitoshi Inanami, Hiroki Nishioka, Kohei Fujimoto, Noriaki Kasayuki, Minoru Yoshiyama

Open access · goldAbstract read
In one paragraph

Article in Clinical cardiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. State of the Art Review: Brachial-Ankle PWV.Journal of atherosclerosis and thrombosis · 2020
    Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Kenichiro OtsukaDepartment of Cardiovascular Medicine, Ishikiri-seiki Hospital, Higashi-osaka, Japan.ORCID https://orcid.org/0000-0003-1359-3143
Koki NakanishiDepartment of Cardiovascular Medicine, Baba Memorial Hospital, Sakai, Japan.ORCID https://orcid.org/0000-0002-5787-8004
Kenei ShimadaDepartment of Cardiovascular Medicine, Kashiba-seiki Hospital, Kashiba, Japan.
Haruo NakamuraDepartment of Cardiovascular Medicine, Ishikiri-seiki Hospital, Higashi-osaka, Japan.
Hitoshi InanamiDepartment of Cardiovascular Medicine, Ishikiri-seiki Hospital, Higashi-osaka, Japan.
Hiroki NishiokaDepartment of Cardiovascular Medicine, Ishikiri-seiki Hospital, Higashi-osaka, Japan.
Kohei FujimotoDepartment of Cardiovascular Medicine, Ishikiri-seiki Hospital, Higashi-osaka, Japan.
Noriaki KasayukiDepartment of Cardiovascular Medicine, Ishikiri-seiki Hospital, Higashi-osaka, Japan.
Minoru YoshiyamaDepartment of Cardiovascular Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan.
Ishikiriseiki Hospital · JPBaba Memorial Hospital · JPOsaka City University · JPToshiba (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough ankle-brachial index (ABI) and brachial-ankle pulse wave velocity (baPWV) are significant predictors of major adverse cardiovascular event (MACE), their prognostic value in association with biomarkers has not been fully evaluated in patients with end-stage kidney disease (ESKD). HYPOTHESIS: We hypothesized that ABI/baPWV would provide better prognostic value independent of biomarkers in ESKD patients.

methodsThis study included 104 ESKD patients treated with maintenance hemodialysis who underwent ABI and baPWV examinations and laboratory tests, including brain-natriuretic peptide, high-sensitive cardiac troponin T (hs-cTnT), and high-sensitive C-reactive protein (hs-CRP). MACE was defined as a composite event of all-cause death, acute coronary syndrome, and stroke.

resultsDuring a mean follow-up of 3.6 ± 1.7 years, a total of 51 MACE were observed. The independent factors associated with MACE were age >75 years (adjusted hazard ratio [HR], 2.15; P < .05), abnormal ABI (adjusted HR, 2.01; P < .05), left ventricular ejection fraction (LVEF) <50% (adjusted HR, 3.33; P < .001), the upper tertile of hs-cTnT (adjusted HR, 2.77; P < .05), and hs-CRP (HR, 1.96; P < .05). However, baPWV did not remain as an independent predictor of MACE in the entire cohort and also in patients without abnormal ABI. The combination of predictors improves the predictive value of MACE, providing increased HR with 4.00 for abnormal ABI + hs-CRP, 4.42 for abnormal ABI + hs-cTnT, and 7.04 for abnormal ABI + LVEF <50% (all P < .001).

conclusionAbnormal ABI is a robust predictor of MACE independent of biomarkers and their combination provides better risk stratification compared with a single predictor in ESKD patients.

Indexed as

AgedAnkle Brachial IndexBiomarkersCardiovascular DiseasesC-Reactive ProteinFemaleFollow-Up StudiesHumansJapanKidney Failure, ChronicMaleNatriuretic Peptide, BrainPredictive Value of TestsPrognosisRetrospective StudiesRisk FactorsBiomarkersC-Reactive ProteinNatriuretic Peptide, BrainTroponin Tarterial stiffnessbiomarkerdialysisperipheral arterial diseaseprognosis

Identifiers

PMID31020665
PMCPMC6605000
OpenAlexW2942419553

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.